Publications

Kristy Lastwika's Bibliography (National Library of Medicine)

  1. Sarrett SM, Rodriguez C, Delaney S, Hosny MM, Sebastiano J, Santos-Coquillat A, Keinanen OM, Carter LM, Lastwika KJ, Lampe PD, Zeglis BM. (2024). Evaluating CD133 as a Radiotheranostic Target in Small Cell Lung Cancer. Molecular Pharmaceutics, 21(3): 1402-1413. PMID: 38331430.
  2. Lastwika KJ and Lampe PD. Breaking Tolerance: Autoantibodies Can Target Protein Posttranslational Modifications. Current Opinion in Biotechnology. 2024. Feb;85:103056. PMID: 38141322.
  3. Lastwika KJ*, Wu W*, Zhang Y, Ma N, Zecevic M, Pipavath SNJ, Randolph TW, Houghton AM, Nair VS, Lampe PD, and Kinahan PE. Multi-omic Biomarkers Improve Indeterminate Pulmonary Nodule Malignancy Risk Assessment. Cancers (Basel). 2023. June; 15(13). PMID: 37444527.
    *Authors contributed equally
  4. Lastwika KJ, Kunhiro AG, Solan JL, Zhang, Y, Taverne, LR, Shelley D, Rho JH, Randolph TW, Li CI, Grogan EL, Massion PP, Fitzpatrick AL, Houghton AM, Lampe PD. Tumor antigens induce autoantibodies with clinical utility in small cell lung cancer. Sci Transl Med. 2023. Jan;15(678). PMIC: 36630482.
  5. Kunhiro AG*, Sarrett SM*, Lastwika KJ*, Solan JL, Pisarenko T, Keinanen O, Rodriguez, Taverme LR, Fitzpatrick AL, Li CI, Houghton AM, Zeglis BM, Lampe PD. CD133 as a biomarker for an autoantibody-to-immunoPET paradigm for the early detection of small cell lung cancer. J Nucl Med. 2022. Apr; 63(6). PMID: 35483965.
    *Authors contributed equally
  6. Lastwika KJ, Dunn CA, Solan JL, Lampe PD. Phosphorylation of Connexin43 at MAPK, PKC or CK1 sites each distinctly alter the kinetics of epidermal wound repair. J Cell Sci. 2019. Sept; 132(18). PMID: 31427427.
  7. Wu W, Pierce LA, Pipavath SNJ, Zhang Y, Lastwika KJ, Lampe PD, Houghton AM, Xia L, Liu H, Kinahan PE. Comparison of prediction models with radiological semantic features and radiomics in pulmonary nodule diagnosis: A case-control study. Eur Radiol. 2019 May 21. PMID:31115618.
  8. Lastwika KJ*, Kargl J*, Zhang Y, Zhu X, Lo E, Shelley D, Ladd JJ, Wu W, Kinahan P, Pipavath SNJ, Randolph TW, Lampe PD, Houghton AM. Tumor-Derived Autoantibodies Identify Malignant Pulmonary Nodules. 2018. Am J Respir Crit Care Med. 199(10):1257-1266. PMID: 30422669.
  9. Garrison CB*, Lastwika KJ*, Zhang Y, Li CI, Lampe PD. Proteomic analysis, immune dysregulation and pathway interconnections with obesity. J Proteome Res. 2017 Dec; 27(6):545-557. PMID: 27769113.
    *Authors contributed equally
  10. Robinson J, Vito R, Fedorenko, I, Gibney G, Lastwika KJ, Grossman D, Chen G, Davies M, Vanbrocklin M, Smalley K, and Holmen S. Resistance mechanisms to genetic suppression of mutant NRAS in melanoma. Melanoma Res., 2017. 27(6):545-557. PMID:29076949.
  11. Lastwika KJ, Wilson W, Li QK, Norris J, Xu H, Ghazarian SR, Kitagawa H, Kawabata S, Taube JM, Yao S, Liu LN and Dennis PA. Control of PD-L1 expression by oncogenic activation of the AKT/mTOR pathway in NSCLC. Cancer Res., 2016; 76(2):227-38. PMID:26637667.
  12. Robinson GL, Robinson JP, Lastwika KJ, Holmen SL, and Vanbrocklin MW. Akt signaling accelerates tumor recurrence following ras inhibition in the context of ink4a/arf loss. Genes Cancer. 2013. 4(11-12):476-85. PMID:24386508.
  13. Vanbrocklin MW, Robinson JP, Lastwika KJ, McKinney AJ, Gach HM, and Holmen SL. Ink4a/Arf loss promotes tumor recurrence following Ras inhibition. Neuro Oncol., 2012. 14(1):34-42. PMID: 22015595.
  14. Robinson JP, VanBrocklin MW, Lastwika KJ, McKinney AM, Brandner S and Holmen SL. Activated MEK induces gliomas in vivo in the context of Ink4a/Arf loss or Akt activation. Oncogene, 2011. 30(11):1341-50. PMID: 21057530.
  15. VanBrocklin MW, Robinson JP, Lastwika KJ, Guilbeault AR, Khoury JD, and Holmen SL. Targeted delivery of NRASQ61R and Cre-recombinase to melanocytes in vivo induces melanoma in Ink4a/Arf lox/lox mice. Pigment Cell and Melanoma Res., 2010. 23(4):531-41. PMID: 20444198.